<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00899691</url>
  </required_header>
  <id_info>
    <org_study_id>040138</org_study_id>
    <secondary_id>04-C-0138</secondary_id>
    <secondary_id>CDR0000363803</secondary_id>
    <nct_id>NCT00899691</nct_id>
  </id_info>
  <brief_title>Study of Hair Samples From Patients With Cancer</brief_title>
  <official_title>Detection and Quantification of Changes in Levels of Protein Expression and Phosphorylation Status Using Human Hair Samples</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institutes of Health Clinical Center (CC)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Studying samples of hair in the laboratory from patients with cancer may help&#xD;
      doctors identify biomarkers related to cancer and predict how well patients will respond to&#xD;
      treatment.&#xD;
&#xD;
      PURPOSE: This laboratory study is looking at hair samples from patients with cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine whether layered membrane technology can quantitatively measure the expression,&#xD;
           activity, and localization of cell growth control and signaling proteins in hair samples&#xD;
           from patients with cancer.&#xD;
&#xD;
        -  Correlate changes in protein expression with expected changes based on planned therapy&#xD;
           in these patients.&#xD;
&#xD;
      OUTLINE: This is a pilot, multicenter study.&#xD;
&#xD;
      Hair samples are obtained from patients at baseline and at the end of study. The samples are&#xD;
      assayed for proteins and phosphorylation status using layered membrane technology. Proteins&#xD;
      analyzed may include vascular endothelial growth factor receptor (VEGFR), Erk1/2, Akt,&#xD;
      epidermal growth factor receptor (EGFR), and c-KIT.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 190 patients will be accrued for this study within 3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2005</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>Obtain data on the detection and quantification of changes in levels of protein expression and phosphorylation status using human hair samples at baseline and after completion of study</measure>
  </primary_outcome>
  <enrollment type="Anticipated">190</enrollment>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>protein expression analysis</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of malignancy&#xD;
&#xD;
          -  Undergoing treatment at the National Cancer Institute's Clinical Center&#xD;
&#xD;
          -  Must have scalp hair&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven K. Libutti, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NCI - Surgery Branch</affiliation>
  </overall_official>
  <verification_date>March 2012</verification_date>
  <study_first_submitted>May 9, 2009</study_first_submitted>
  <study_first_submitted_qc>May 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2009</study_first_posted>
  <last_update_submitted>March 14, 2012</last_update_submitted>
  <last_update_submitted_qc>March 14, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 15, 2012</last_update_posted>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

